Novo Nordisk, Sanofi Cap Feud Over Insulin Pen

Law360, New York (January 12, 2010, 3:19 PM EST) -- Novo Nordisk A/S has resolved a dispute with Sanofi-Aventis SA over its insulin pen Solostar, a product Novo claimed infringed the patent for its top-selling insulin device FlexPen.

Judge Mary Cooper of the U.S. District Court for the District of New Jersey signed off on a joint stipulation of dismissal with prejudice Monday.

Attorneys for Sanofi-Aventis and Novo could not immediately be reached to comment on the apparent settlement, which puts to rest more than two years of litigation.

Denmark-based drugmaker Novo originally sued Sanofi-Aventis in...
To view the full article, register now.